8-K/A
MCKESSON CORP (MCK)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): February 5, 2025
McKESSON CORPORATION
(Exact Name of Registrant as Specified in Charter)
| Delaware | 1-13252 | 94-3207296 |
|---|---|---|
| (State or Other Jurisdiction<br>of Incorporation) | (Commission<br>File Number) | (I.R.S. Employer<br>Identification No.) |
6555 State Hwy 161
Irving, TX 75039
(Address of Principal Executive Offices, and Zip Code)
(972) 446-4800
Registrant’s Telephone Number, Including Area Code
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading<br>Symbol(s) | Name of each exchange<br>on which registered |
|---|---|---|
| Common stock, $0.01 par value | MCK | New York Stock Exchange |
| 1.500% Notes due 2025 | MCK25 | New York Stock Exchange |
| 1.625% Notes due 2026 | MCK26 | New York Stock Exchange |
| 3.125% Notes due 2029 | MCK29 | New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Explanatory Note
This Amendment to the Current Report on Form 8-K filed by McKesson Corporation (the “Company” or “McKesson”) on February 5, 2025 is being filed to solely include a dated conformed signature on the cover page.
Item 2.02 Results of Operations and Financial Condition.
On February 5, 2025, McKesson reported the Company’s preliminary results for the quarter ended on December 31, 2024 which are attached hereto as Exhibit 99.1.
The information contained in this Form 8-K, including Exhibit 99.1, is furnished to the Securities and Exchange Commission (the “Commission”), but shall not be deemed “filed” with the Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description |
|---|---|
| 99.1 | Earnings release issued by the Company dated February 5, 2025 |
| 104 | Cover Page Interactive Data File - the cover page iXBRL tags are embedded within the Inline XBRL document |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 5, 2025
| McKesson Corporation | ||
|---|---|---|
| By: | /s/ Britt J. Vitalone | |
| Britt J. Vitalone | ||
| Executive Vice President and | ||
| Chief Financial Officer |
Document
Exhibit 99.1
McKESSON CORPORATION REPORTS FISCAL 2025 THIRD QUARTER RESULTS
AND RAISES FULL YEAR ADJUSTED EPS GUIDANCE
IRVING, Texas, February 5, 2025 - McKesson Corporation (NYSE:MCK) today announced results for the third quarter ended December 31, 2024.
Third Quarter Highlights:
•Consolidated revenues of $95.3 billion increased 18%.
•Earnings per diluted share of $6.95 increased $2.53.
•Adjusted Earnings per Diluted Share of $8.03 increased 4%.
•McKesson signed a definitive agreement to acquire a controlling interest in PRISM Vision Holdings, LLC.
•McKesson closed the transaction to sell its Canada-based Rexall and Well.ca retail businesses on December 30, 2024.
Fiscal 2025 Outlook:
•Adjusted Earnings per Diluted Share guidance range raised and narrowed to $32.55 to $32.95, from the previous range of $32.40 to $33.00.
•Fiscal 2025 Adjusted Earnings per Diluted Share guidance range indicates 19% to 20% growth compared to prior year.
•The Company does not forecast GAAP earnings per diluted share1.
"McKesson reported strong third quarter operational results with broad-based Revenue growth of 18% and Adjusted Operating Profit growth of 16%. Our performance reflects the strength and momentum across the enterprise. I would like to thank the McKesson employees for their continued dedication to advancing our mission," said Brian Tyler, chief executive officer. "We remain committed to our enterprise growth strategy, including our growth pillars within oncology and biopharma services. This strategy has enabled our strong results and is a foundation for balanced growth and value creation. Based on our third quarter performance, we are raising and narrowing our guidance range for fiscal 2025 Adjusted Earnings per Diluted Share to $32.55 to $32.95."
Mr. Tyler added, "We are also pleased to announce the signing of a definitive agreement to acquire a controlling interest in PRISM Vision Holdings, in support of our leadership in community practice management and specialty solutions. With this transaction, we intend to develop a leading platform for retinal care, delivering differentiated solutions and value across providers, biopharma partners, and patients. McKesson has a long track record of leading practice management and clinical research outcomes with our differentiated Oncology platform, and we are excited to leverage this expertise to serve the high-growth area of retina and ophthalmology. We are executing against our strategy and expanding our suite of solutions to continue to pursue our purpose of advancing health outcomes for all."
1 See below under "Fiscal 2025 Outlook" for full explanation
Fiscal 2025 Third Quarter Result Summary
| Third Quarter | Year-to-Date | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ($ in millions, except per share amounts) | FY25 | FY24 | Change | FY25 | FY24 | Change | ||||||
| Revenues | $ | 95,294 | $ | 80,898 | 18 | % | $ | 268,228 | $ | 232,596 | 15 | % |
| Operating Profit | 1,293 | 676 | 91 | 3,064 | 2,791 | 10 | ||||||
| Adjusted Operating Profit2 | 1,463 | 1,261 | 16 | 4,059 | 3,639 | 12 | ||||||
| Net income attributable to McKesson Corporation | 879 | 589 | 49 | 2,035 | 2,211 | (8) | ||||||
| Adjusted Earnings2 | 1,016 | 1,032 | (2) | 2,960 | 2,866 | 3 | ||||||
| Earnings per diluted common share attributable to McKesson Corporation | 6.95 | 4.42 | 57 | 15.80 | 16.39 | (4) | ||||||
| Adjusted Earnings per Diluted Share2 | 8.03 | 7.74 | 4 | 22.97 | 21.24 | 8 | ||||||
| 2 Adjusted results in this earnings release are non-GAAP financial measures; refer to the accompanying definitions and reconciliation schedules |
Third quarter revenues were $95.3 billion, an increase of 18% from a year ago, primarily driven by growth in the U.S. Pharmaceutical segment, due to increased prescription volumes, including higher volumes from retail national account customers and specialty products, and growth in the oncology platform.
Third quarter earnings per diluted share was $6.95 compared to $4.42 a year ago, an increase of $2.53, due to the prior year increase of the provision for bad debts related to the Rite Aid bankruptcy within the U.S. Pharmaceutical segment.
Third quarter Adjusted Earnings per Diluted Share was $8.03 compared to $7.74 a year ago, an increase of 4%, primarily driven by strong operational growth and a lower share count, partially offset by a higher tax rate. Third quarter Adjusted Earnings per Diluted Share also included pre-tax gains of $6 million associated with McKesson Ventures' equity investments, compared to pre-tax losses of $8 million in the third quarter of fiscal 2024.
For the first nine months of the fiscal year, McKesson returned $3.1 billion of cash to shareholders, which included $2.8 billion of common stock repurchases and $254 million of dividend payments. During the first nine months of the fiscal year, McKesson used cash from operations of $1.7 billion, and invested $581 million in capital expenditures, resulting in negative Free Cash Flow of $2.2 billion.
Business Highlights
•McKesson elected Lynne Doughtie and Dr. Julie Gerberding as New Directors on February 3, 2025, increasing the board to 13 members, 12 of whom are independent.
◦Lynne Doughtie brings accounting and finance expertise as the former Chair and Chief Executive Officer of KPMG U.S. Ms. Doughtie has depth of experience across various industries, including technology, healthcare, and financial services. Ms. Doughtie will serve on the Audit Committee and the Finance Committee.
◦Dr. Julie Gerberding brings extensive executive experience in the healthcare industry and public policy as the Chief Executive Officer of the Foundation for the National Institutes of Health. Previously, she served as the Executive Vice President and Chief Patient Officer at Merck & Co. and the Director of the Centers for Disease Control and Prevention. Dr. Gerberding will serve on the Compliance Committee and the Compensation and Talent Committee.
•McKesson signed a definitive agreement to acquire an 80% controlling interest in PRISM Vision Holdings, LLC, a leading provider of general ophthalmology and retina management services. The transaction is subject to customary closing conditions, including required regulatory clearance.
•On December 30, 2024, McKesson closed the transaction to sell its Canada-based Rexall and Well.ca retail businesses.
U.S. Pharmaceutical Segment
•Revenues were $87.1 billion, an increase of 19%, driven by increased prescription volumes, including higher volumes from retail national account customers and specialty products, and growth in the oncology platform.
•Segment Operating Profit was $854 million. Adjusted Segment Operating Profit was $944 million, an increase of 14%, driven by growth in the distribution of specialty products to providers and health systems.
Prescription Technology Solutions Segment
•Revenues were $1.4 billion, an increase of 14%, driven by increased prescription volumes in our third-party logistics and technology services businesses.
•Segment Operating Profit was $219 million. Adjusted Segment Operating Profit was $235 million, an increase of 22%, driven by growth in access and affordability solutions.
Medical-Surgical Solutions Segment
•Revenues were $2.9 billion, a decrease of 3%, driven by lower contributions from illness season vaccines and testing in the primary care channel.
•Segment Operating Profit was $269 million. Adjusted Segment Operating Profit was $294 million, an increase of 4%, driven by operational efficiencies from the cost optimization initiatives, partially offset by lower contributions in the primary care channel.
International Segment
•Revenues were $3.9 billion, an increase of 6%, driven by higher pharmaceutical distribution volumes in the Canadian business.
•Segment Operating Profit was $111 million. Adjusted Segment Operating Profit was $124 million, an increase of 18%, driven by higher pharmaceutical distribution volumes in the Canadian business and the discontinued recording of depreciation and amortization on Canada-based Rexall and Well.ca retail businesses, which were divested during the quarter.
Fiscal 2025 Outlook
McKesson does not provide forward-looking guidance on a GAAP basis as the company is unable to provide a quantitative reconciliation of forward-looking Non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort. McKesson cannot reasonably forecast LIFO inventory-related adjustments, certain litigation loss and gain contingencies, restructuring, impairment and related charges, and other adjustments, which are difficult to predict and estimate. These items are generally uncertain and depend on various factors, many of which are beyond the company's control, and as such, any associated estimate and its impact on GAAP performance could vary materially.
McKesson is raising and narrowing fiscal 2025 Adjusted Earnings per Diluted Share guidance to $32.55 to $32.95 from the previous range of $32.40 to $33.00.
Fiscal 2025 Adjusted Earnings per Diluted Share guidance includes $0.57 related to year-to-date gains associated with McKesson Ventures' equity investments.
Additional modeling considerations will be provided in the earnings call presentation.
Conference Call Details
McKesson has scheduled a conference call for today, Wednesday, February 5th at 4:30 PM ET to discuss the company’s financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website at investor.mckesson.com.
Upcoming Investor Event
McKesson management will be participating in the following investor event:
•TD Cowen 45th Annual Healthcare Conference, March 4, 2025
The audio webcasts, and a complete listing of upcoming events for the investment community, including details and updates, will be available on McKesson's Investor Relations website.
Non-GAAP Financial Measures
GAAP refers to the U.S. generally accepted accounting principles. This press release includes GAAP financial measures as well as Non-GAAP financial measures, including Adjusted Gross Profit, Adjusted Operating Expenses, Adjusted Other Income, Adjusted Interest Expense, Adjusted Income Tax Expense, Adjusted Earnings, Adjusted Earnings per Diluted Share, Adjusted Segment Operating Profit, Adjusted Segment Operating Profit Margin, Adjusted Corporate Expenses, Adjusted Operating Profit, and Free Cash Flow which are financial measures not calculated in accordance with GAAP. Refer to the “Supplemental Non-GAAP Financial Information” section of the accompanying financial statement tables for the definitions and usefulness of the company’s Non-GAAP financial measures and the attached schedules for reconciliations of the differences between the Non-GAAP financial measures and their most directly comparable GAAP financial measures.
Cautionary Statements
This earnings release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by their use of terminology such as “believes,” “expects,” “anticipates,” “may,” “will,” “should,” “seeks,” “approximately,” “intends,” “projects,” “plans,” “estimates,” “targets,” or the negative of these words or other comparable terminology. The discussion of anticipated transaction closings, synergies, litigation outcomes, financial outlook, guidance, trends, strategy, plans, assumptions, expectations, commitments, and intentions may also include forward-looking statements. Readers should not place undue reliance on forward-looking statements, such as financial performance forecasts, which speak only as of the date they are first made. Except to the extent required by law, we undertake no obligation to update or revise our forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated, or implied. Although it is not possible to predict or identify all such risks and uncertainties, we encourage investors to read the risk factors described in our publicly available filings with the Securities and Exchange Commission and news releases.
These risk factors include, but are not limited to: we experience costly and disruptive legal disputes and settlements, including regarding our role in distributing controlled substances such as opioids; we might experience losses not covered by insurance or indemnification; we are subject to frequently changing, extensive, complex, and challenging healthcare and other laws; we might be adversely impacted by regulatory delays or other difficulties with acquisitions or divestitures such as the transactions described in this press release; we from time to time record significant charges from impairment to goodwill, intangibles, and other long-lived assets; we experience cybersecurity incidents that might significantly compromise our technology systems or might result in material data breaches; we may be unsuccessful in achieving our strategic growth objectives; we may be unsuccessful in our efforts to implement initiatives to reduce or optimize our costs; we are impacted by customer purchase reductions, contract non-renewals, payment defaults, and bankruptcies; our contracts with government entities involve future funding and compliance risks; we might be harmed by changes in our relationships or contracts with suppliers; our use of third-party data is subject to limitations that could impede the growth of our data services business; we might be adversely impacted by healthcare reform such as changes in pricing and reimbursement models; we might be adversely impacted by competition and industry consolidation; we are adversely impacted by changes or disruptions in product supply and have had difficulties in sourcing or selling products due to a variety of causes; we might be adversely impacted as a result of our distribution of generic pharmaceuticals; we might be adversely impacted by changes in the economic environments in which we operate; changes affecting capital and credit markets might impede access to credit, increase borrowing costs, and disrupt banking services for us and our customers and suppliers and might impair the financial soundness of our customers and suppliers; we might be adversely
impacted by changes in tax legislation or challenges to our tax positions; we might be adversely impacted by events outside of our control, such as widespread public health issues, natural disasters, political events and other catastrophic events; we may be adversely affected by global climate change or by legal, regulatory, or market responses to such change; and governance issues and regulations, including those related to social issues, climate change, and sustainability, and stakeholder response thereto may have an adverse effect on our business, financial condition, and results of operations and damage our reputation.
About McKesson Corporation
McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Our Stories.
Contacts:
Investors
Investors@McKesson.com
Media Relations
MediaRelations@McKesson.com
Schedule 1
McKESSON CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (GAAP)
(unaudited)
(in millions, except per share amounts)
| Three Months Ended December 31, | Nine Months Ended December 31, | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | 2023 | Change | 2024 | 2023 | Change | |||||||
| Revenues | $ | 95,294 | $ | 80,898 | 18 | % | $ | 268,228 | $ | 232,596 | 15 | % |
| Cost of sales | (92,010) | (77,746) | 18 | (258,544) | (223,353) | 16 | ||||||
| Gross profit | 3,284 | 3,152 | 4 | 9,684 | 9,243 | 5 | ||||||
| Selling, distribution, general, and administrative expenses | (2,028) | (2,506) | (19) | (6,532) | (6,468) | 1 | ||||||
| Claims and litigation charges, net | — | — | — | (108) | 2 | — | ||||||
| Restructuring, impairment, and related charges, net | (32) | (4) | 700 | (213) | (84) | 154 | ||||||
| Total operating expenses | (2,060) | (2,510) | (18) | (6,853) | (6,550) | 5 | ||||||
| Operating income | 1,224 | 642 | 91 | 2,831 | 2,693 | 5 | ||||||
| Other income, net | 69 | 34 | 103 | 233 | 98 | 138 | ||||||
| Interest expense | (67) | (64) | 5 | (220) | (172) | 28 | ||||||
| Income before income taxes | 1,226 | 612 | 100 | 2,844 | 2,619 | 9 | ||||||
| Income tax benefit (expense) | (298) | 18 | — | (669) | (289) | 131 | ||||||
| Net income | 928 | 630 | 47 | 2,175 | 2,330 | (7) | ||||||
| Net income attributable to noncontrolling interests | (49) | (41) | 20 | (140) | (119) | 18 | ||||||
| Net income attributable to McKesson Corporation | $ | 879 | $ | 589 | 49 | % | $ | 2,035 | $ | 2,211 | (8) | % |
| Earnings per common share attributable to McKesson Corporation (a) | ||||||||||||
| Diluted | $ | 6.95 | $ | 4.42 | 57 | % | $ | 15.80 | $ | 16.39 | (4) | % |
| Basic | $ | 6.98 | $ | 4.45 | 57 | % | $ | 15.88 | $ | 16.49 | (4) | % |
| Dividends declared per common share | $ | 0.71 | $ | 0.62 | 15 | % | $ | 2.04 | $ | 1.78 | 15 | % |
| Weighted-average common shares outstanding | ||||||||||||
| Diluted | 126.6 | 133.3 | (5) | % | 128.8 | 134.9 | (5) | % | ||||
| Basic | 126.0 | 132.5 | (5) | 128.2 | 134.0 | (4) | % |
(a)Certain computations may reflect rounding adjustments.
Any percentage changes displayed above which are not meaningful are displayed as zero percent.
Refer to our applicable filings with the SEC for additional disclosures including our Quarterly Reports on Form 10-Q for fiscal 2025 and 2024 as well as our
Annual Report on Form 10-K for fiscal 2024.
Schedule 2
McKESSON CORPORATION
RECONCILIATION OF GAAP OPERATING RESULTS TO ADJUSTED RESULTS (NON-GAAP)
(unaudited)
(in millions, except per share amounts)
| Three Months Ended December 31, | Nine Months Ended December 31, | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | 2023 | Change | 2024 | 2023 | Change | |||||||
| Net income (GAAP) | $ | 928 | $ | 630 | 47 | % | $ | 2,175 | $ | 2,330 | (7) | % |
| Net income attributable to noncontrolling interests (GAAP) | (49) | (41) | 20 | (140) | (119) | 18 | ||||||
| Net income attributable to McKesson Corporation (GAAP) | 879 | 589 | 49 | 2,035 | 2,211 | (8) | ||||||
| Pre-tax adjustments: | ||||||||||||
| Amortization of acquisition-related intangibles | 53 | 62 | (15) | 176 | 186 | (5) | ||||||
| Transaction-related expenses and adjustments (1) (2) | 32 | 21 | 52 | 712 | (7) | — | ||||||
| LIFO inventory-related adjustments | 89 | 2 | — | 85 | 89 | (4) | ||||||
| Gains from antitrust legal settlements | (31) | (23) | 35 | (184) | (220) | (16) | ||||||
| Restructuring, impairment, and related charges, net (3) | 32 | 4 | 700 | 276 | 84 | 229 | ||||||
| Claims and litigation charges, net (4) | — | — | — | 108 | (2) | — | ||||||
| Other adjustments, net (5) (6) | — | 525 | (100) | (162) | 735 | (122) | ||||||
| Income tax effect on pre-tax adjustments | (37) | (145) | (74) | (82) | (204) | (60) | ||||||
| Net income attributable to noncontrolling interests effect on pre-tax adjustments | (1) | (3) | (67) | (4) | (6) | (33) | ||||||
| Adjusted Earnings (Non-GAAP) | $ | 1,016 | $ | 1,032 | (2) | % | $ | 2,960 | $ | 2,866 | 3 | % |
| Earnings per diluted common share attributable to McKesson Corporation (GAAP) (a) | $ | 6.95 | $ | 4.42 | 57 | % | $ | 15.80 | $ | 16.39 | (4) | % |
| After-tax adjustments: | ||||||||||||
| Amortization of acquisition-related intangibles | 0.31 | 0.35 | (11) | 1.00 | 1.05 | (5) | ||||||
| Transaction-related expenses and adjustments | 0.24 | 0.14 | 71 | 5.47 | 0.04 | — | ||||||
| LIFO inventory-related adjustments | 0.52 | 0.02 | — | 0.49 | 0.49 | — | ||||||
| Gains from antitrust legal settlements | (0.18) | (0.13) | 38 | (1.06) | (1.21) | (12) | ||||||
| Restructuring, impairment, and related charges, net | 0.19 | 0.03 | 533 | 1.58 | 0.47 | 236 | ||||||
| Claims and litigation charges, net | — | — | — | 0.62 | (0.02) | — | ||||||
| Other adjustments, net | — | 2.91 | (100) | (0.93) | 4.03 | (123) | ||||||
| Adjusted Earnings per Diluted Share (Non-GAAP) (a) | $ | 8.03 | $ | 7.74 | 4 | % | $ | 22.97 | $ | 21.24 | 8 | % |
| Diluted weighted-average common shares outstanding | 126.6 | 133.3 | (5) | % | 128.8 | 134.9 | (5) | % |
(a)Certain computations may reflect rounding adjustments.
Any percentage changes displayed above which are not meaningful are displayed as zero percent.
Refer to the section entitled "Financial Statement Notes" of this release.
For more information relating to the Adjusted Earnings (Non-GAAP) and Adjusted Earnings per Diluted Share (Non-GAAP) definitions, refer to the section entitled “Supplemental Non-GAAP Financial Information” of this release.
Schedule 2 (continued)
McKESSON CORPORATION
RECONCILIATION OF GAAP OPERATING RESULTS TO ADJUSTED RESULTS (NON-GAAP)
(unaudited)
(in millions)
| Three Months Ended December 31, | Nine Months Ended December 31, | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | 2023 | Change | 2024 | 2023 | Change | |||||||
| Gross profit (GAAP) | $ | 3,284 | $ | 3,152 | 4 | % | $ | 9,684 | $ | 9,243 | 5 | % |
| Pre-tax adjustments: | ||||||||||||
| LIFO inventory-related adjustments | 89 | 2 | — | 85 | 89 | (4) | ||||||
| Gains from antitrust legal settlements | (31) | (23) | 35 | (184) | (220) | (16) | ||||||
| Restructuring, impairment, and related charges, net (3) | — | — | — | 63 | — | — | ||||||
| Adjusted Gross Profit (Non-GAAP) | $ | 3,342 | $ | 3,131 | 7 | % | $ | 9,648 | $ | 9,112 | 6 | % |
| Total operating expenses (GAAP) | $ | (2,060) | $ | (2,510) | (18) | % | $ | (6,853) | $ | (6,550) | 5 | % |
| Pre-tax adjustments: | ||||||||||||
| Amortization of acquisition-related intangibles | 53 | 62 | (15) | 176 | 186 | (5) | ||||||
| Transaction-related expenses and adjustments (1) (2) | 27 | 15 | 80 | 697 | (24) | — | ||||||
| Restructuring, impairment, and related charges, net (3) | 32 | 4 | 700 | 213 | 84 | 154 | ||||||
| Claims and litigation charges, net (4) | — | — | — | 108 | (2) | — | ||||||
| Other adjustments, net (5) | — | 525 | (100) | (205) | 735 | (128) | ||||||
| Adjusted Operating Expenses (Non-GAAP) | $ | (1,948) | $ | (1,904) | 2 | % | $ | (5,864) | $ | (5,571) | 5 | % |
| Other income, net (GAAP) | $ | 69 | $ | 34 | 103 | % | $ | 233 | $ | 98 | 138 | % |
| Pre-tax adjustments: | ||||||||||||
| Transaction-related expenses and adjustments | — | — | — | (1) | — | — | ||||||
| Other adjustments, net (6) | — | — | — | 43 | — | — | ||||||
| Adjusted Other Income (Non-GAAP) | $ | 69 | $ | 34 | 103 | % | $ | 275 | $ | 98 | 181 | % |
| Interest expense (GAAP) | $ | (67) | $ | (64) | 5 | % | $ | (220) | $ | (172) | 28 | % |
| Pre-tax adjustments: | ||||||||||||
| Transaction-related expenses and adjustments | 5 | 6 | (17) | 16 | 17 | (6) | ||||||
| Adjusted Interest Expense (Non-GAAP) | $ | (62) | $ | (58) | 7 | % | $ | (204) | $ | (155) | 32 | % |
| Income tax benefit (expense) (GAAP) | $ | (298) | $ | 18 | — | % | $ | (669) | $ | (289) | 131 | % |
| Tax adjustments: | ||||||||||||
| Amortization of acquisition-related intangibles | (13) | (13) | — | (43) | (40) | 8 | ||||||
| Transaction-related expenses and adjustments (1) (2) | (1) | — | — | (8) | 14 | (157) | ||||||
| LIFO inventory-related adjustments | (23) | (1) | — | (22) | (23) | (4) | ||||||
| Gains from antitrust legal settlements | 8 | 6 | 33 | 48 | 57 | (16) | ||||||
| Restructuring, impairment, and related charges, net (3) | (8) | (1) | 700 | (72) | (21) | 243 | ||||||
| Claims and litigation charges, net (4) | — | — | — | (28) | — | — | ||||||
| Other adjustments, net (5) (6) | — | (136) | (100) | 43 | (191) | 123 | ||||||
| Adjusted Income Tax Expense (Non-GAAP) | $ | (335) | $ | (127) | 164 | % | $ | (751) | $ | (493) | 52 | % |
Any percentage changes displayed above which are not meaningful are displayed as zero percent.
Refer to the section entitled "Financial Statement Notes" of this release.
For more information relating to the Adjusted Gross Profit (Non-GAAP), Adjusted Operating Expenses (Non-GAAP), Adjusted Other Income (Non-GAAP), Adjusted Interest Expense (Non-GAAP), and Adjusted Income Tax Expense (Non-GAAP) definitions, refer to the section entitled “Supplemental Non-GAAP Financial Information” of this release.
Schedule 3
McKESSON CORPORATION
RECONCILIATION OF GAAP SEGMENT OPERATING RESULTS TO ADJUSTED RESULTS (NON-GAAP)
(unaudited)
(in millions)
| Three Months Ended December 31, | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | 2023 | Change | |||||||||||||||||||
| As reported (GAAP) | Adjustments | As adjusted (Non-GAAP) | As reported (GAAP) | Adjustments | As adjusted (Non-GAAP) | As reported (GAAP) | As adjusted (Non-GAAP) | ||||||||||||||
| REVENUES | |||||||||||||||||||||
| U.S. Pharmaceutical | $ | 87,110 | $ | — | $ | 87,110 | $ | 73,023 | $ | — | $ | 73,023 | 19 | % | 19 | % | |||||
| Prescription Technology Solutions | 1,371 | — | 1,371 | 1,205 | — | 1,205 | 14 | 14 | |||||||||||||
| Medical-Surgical Solutions | 2,949 | — | 2,949 | 3,031 | — | 3,031 | (3) | (3) | |||||||||||||
| International | 3,860 | — | 3,860 | 3,639 | — | 3,639 | 6 | 6 | |||||||||||||
| Corporate | 4 | — | 4 | — | — | — | — | — | |||||||||||||
| Revenues | $ | 95,294 | $ | — | $ | 95,294 | $ | 80,898 | $ | — | $ | 80,898 | 18 | % | 18 | % | |||||
| OPERATING PROFIT | |||||||||||||||||||||
| U.S. Pharmaceutical (3) | $ | 854 | $ | 90 | $ | 944 | $ | 307 | $ | 521 | $ | 828 | 178 | % | 14 | % | |||||
| Prescription Technology Solutions (2) | 219 | 16 | 235 | 178 | 15 | 193 | 23 | 22 | |||||||||||||
| Medical-Surgical Solutions (3) | 269 | 25 | 294 | 268 | 14 | 282 | — | 4 | |||||||||||||
| International (1) | 111 | 13 | 124 | 126 | (21) | 105 | (12) | 18 | |||||||||||||
| Subtotal | 1,453 | 144 | 1,597 | 879 | 529 | 1,408 | 65 | 13 | |||||||||||||
| Corporate expenses, net (1) (3) | (160) | 26 | (134) | (203) | 56 | (147) | (21) | (9) | |||||||||||||
| Income before interest expense and income taxes | $ | 1,293 | $ | 170 | $ | 1,463 | $ | 676 | $ | 585 | $ | 1,261 | 91 | % | 16 | % | |||||
| OPERATING PROFIT AS A % OF REVENUES | |||||||||||||||||||||
| U.S. Pharmaceutical | 0.98 | % | 1.08 | % | 0.42 | % | 1.13 | % | 56 | bp | (5) | bp | |||||||||
| Prescription Technology Solutions | 15.97 | 17.14 | 14.77 | 16.02 | 120 | 112 | |||||||||||||||
| Medical-Surgical Solutions | 9.12 | 9.97 | 8.84 | 9.30 | 28 | 67 | |||||||||||||||
| International | 2.88 | 3.21 | 3.46 | 2.89 | (58) | 32 |
Any percentage changes displayed above which are not meaningful are displayed as zero percent.
Refer to the section entitled "Financial Statement Notes" of this release.
For more information relating to the Adjusted Segment Operating Profit (Non-GAAP), Adjusted Operating Profit (Non-GAAP), Adjusted Corporate Expenses (Non-GAAP), and Adjusted Segment Operating Profit Margin (Non-GAAP) definitions, refer to the section entitled “Supplemental Non-GAAP Financial Information” of this release.
Schedule 3 (continued)
McKESSON CORPORATION
RECONCILIATION OF GAAP SEGMENT OPERATING RESULTS TO ADJUSTED RESULTS (NON-GAAP)
(unaudited)
(in millions)
| Nine Months Ended December 31, | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | 2023 | Change | |||||||||||||||||||
| As reported (GAAP) | Adjustments | As adjusted (Non-GAAP) | As reported (GAAP) | Adjustments | As adjusted (Non-GAAP) | As reported (GAAP) | As adjusted (Non-GAAP) | ||||||||||||||
| REVENUES | |||||||||||||||||||||
| U.S. Pharmaceutical | $ | 244,551 | $ | — | $ | 244,551 | $ | 209,949 | $ | — | $ | 209,949 | 16 | % | 16 | % | |||||
| Prescription Technology Solutions | 3,877 | — | 3,877 | 3,589 | — | 3,589 | 8 | 8 | |||||||||||||
| Medical-Surgical Solutions | 8,533 | — | 8,533 | 8,476 | — | 8,476 | 1 | 1 | |||||||||||||
| International | 11,260 | — | 11,260 | 10,582 | — | 10,582 | 6 | 6 | |||||||||||||
| Corporate | 7 | — | 7 | — | — | — | — | — | |||||||||||||
| Revenues | $ | 268,228 | $ | — | $ | 268,228 | $ | 232,596 | $ | — | $ | 232,596 | 15 | % | 15 | % | |||||
| OPERATING PROFIT | |||||||||||||||||||||
| U.S. Pharmaceutical (3) (4) (5) (6) | $ | 2,710 | $ | (49) | $ | 2,661 | $ | 1,727 | $ | 687 | $ | 2,414 | 57 | % | 10 | % | |||||
| Prescription Technology Solutions (2) | 627 | 49 | 676 | 647 | (22) | 625 | (3) | 8 | |||||||||||||
| Medical-Surgical Solutions (3) | 546 | 191 | 737 | 739 | 32 | 771 | (26) | (4) | |||||||||||||
| International (1) | (307) | 633 | 326 | 249 | 35 | 284 | (223) | 15 | |||||||||||||
| Subtotal | 3,576 | 824 | 4,400 | 3,362 | 732 | 4,094 | 6 | 7 | |||||||||||||
| Corporate expenses, net (1) (3) (4) (7) | (512) | 171 | (341) | (571) | 116 | (455) | (10) | (25) | |||||||||||||
| Income before interest expense and income taxes | $ | 3,064 | $ | 995 | $ | 4,059 | $ | 2,791 | $ | 848 | $ | 3,639 | 10 | % | 12 | % | |||||
| OPERATING PROFIT AS A % OF REVENUES | |||||||||||||||||||||
| U.S. Pharmaceutical | 1.11 | % | 1.09 | % | 0.82 | % | 1.15 | % | 29 | bp | (6) | bp | |||||||||
| Prescription Technology Solutions | 16.17 | 17.44 | 18.03 | 17.41 | (186) | 3 | |||||||||||||||
| Medical-Surgical Solutions | 6.40 | 8.64 | 8.72 | 9.10 | (232) | (46) | |||||||||||||||
| International | (2.73) | 2.90 | 2.35 | 2.68 | (508) | 22 |
Any percentage changes displayed above which are not meaningful are displayed as zero percent.
Refer to the section entitled "Financial Statement Notes" of this release.
For more information relating to the Adjusted Segment Operating Profit (Non-GAAP), Adjusted Operating Profit (Non-GAAP), Adjusted Corporate Expenses (Non-GAAP), and Adjusted Segment Operating Profit Margin (Non-GAAP) definitions, refer to the section entitled “Supplemental Non-GAAP Financial Information” of this release.
Schedule 4
McKESSON CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)
(in millions, except per share amounts)
| December 31, 2024 | March 31, 2024 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current assets | ||||
| Cash and cash equivalents | $ | 1,131 | $ | 4,583 |
| Receivables, net | 25,831 | 21,622 | ||
| Inventories, net | 23,837 | 21,139 | ||
| Prepaid expenses and other | 942 | 626 | ||
| Total current assets | 51,741 | 47,970 | ||
| Property, plant, and equipment, net | 2,397 | 2,316 | ||
| Operating lease right-of-use assets | 1,758 | 1,729 | ||
| Goodwill | 10,004 | 10,132 | ||
| Intangible assets, net | 1,509 | 2,110 | ||
| Other non-current assets | 3,672 | 3,186 | ||
| Total assets | $ | 71,081 | $ | 67,443 |
| LIABILITIES AND DEFICIT | ||||
| Current liabilities | ||||
| Drafts and accounts payable | $ | 49,689 | $ | 47,097 |
| Short-term borrowing | 2,425 | — | ||
| Current portion of long-term debt | 1,165 | 50 | ||
| Current portion of operating lease liabilities | 256 | 295 | ||
| Liabilities held for sale | — | — | ||
| Other accrued liabilities | 5,027 | 4,915 | ||
| Total current liabilities | 58,562 | 52,357 | ||
| Long-term debt | 4,422 | 5,579 | ||
| Long-term deferred tax liabilities | 1,092 | 917 | ||
| Long-term operating lease liabilities | 1,489 | 1,466 | ||
| Long-term litigation liabilities | 5,617 | 6,113 | ||
| Other non-current liabilities | 2,603 | 2,610 | ||
| McKesson Corporation stockholders’ deficit | ||||
| Preferred stock, $0.01 par value, 100 shares authorized, no shares issued or outstanding | — | — | ||
| Common stock, $0.01 par value, 800 shares authorized, 279 and 278 shares issued at December 31, 2024 and March 31, 2024, respectively | 3 | 3 | ||
| Additional paid-in capital | 8,291 | 8,048 | ||
| Retained earnings | 16,752 | 14,978 | ||
| Accumulated other comprehensive loss | (989) | (881) | ||
| Other | — | — | ||
| Treasury shares, at cost, 153 and 148 shares at December 31, 2024 and March 31, 2024, respectively | (27,141) | (24,119) | ||
| Total McKesson Corporation stockholders’ deficit | (3,084) | (1,971) | ||
| Noncontrolling interests | 380 | 372 | ||
| Total deficit | (2,704) | (1,599) | ||
| Total liabilities and deficit | $ | 71,081 | $ | 67,443 |
Schedule 5
McKESSON CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(in millions)
| Nine Months Ended December 31, | ||||
|---|---|---|---|---|
| 2024 | 2023 | |||
| OPERATING ACTIVITIES | ||||
| Net income | $ | 2,175 | $ | 2,330 |
| Adjustments to reconcile to net cash used in operating activities: | ||||
| Depreciation | 182 | 191 | ||
| Amortization | 303 | 284 | ||
| Asset impairment charges | 83 | 28 | ||
| Deferred taxes | 150 | (552) | ||
| Charges associated with last-in, first-out inventory method | 85 | 89 | ||
| Non-cash operating lease expense | 179 | 186 | ||
| Loss (gain) from sales of businesses and investments | 571 | (17) | ||
| Provision for bad debts | (144) | 780 | ||
| Other non-cash items | 211 | 137 | ||
| Changes in assets and liabilities: | ||||
| Receivables | (4,064) | (4,298) | ||
| Inventories | (3,134) | (2,384) | ||
| Drafts and accounts payable | 2,677 | 4,163 | ||
| Operating lease liabilities | (305) | (247) | ||
| Taxes | (288) | (40) | ||
| Litigation liabilities | (386) | (529) | ||
| Other | 42 | 46 | ||
| Net cash provided by (used in) operating activities | (1,663) | 167 | ||
| INVESTING ACTIVITIES | ||||
| Payments for property, plant, and equipment | (368) | (243) | ||
| Capitalized software expenditures | (213) | (175) | ||
| Acquisitions, net of cash, cash equivalents, and restricted cash acquired | (3) | (6) | ||
| Proceeds from sales of businesses and investments, net | 83 | 47 | ||
| Other | (8) | (118) | ||
| Net cash used in investing activities | (509) | (495) | ||
| FINANCING ACTIVITIES | ||||
| Proceeds from short-term borrowings | 11,395 | 4,770 | ||
| Repayments of short-term borrowings | (8,970) | (4,552) | ||
| Proceeds from issuances of long-term debt | 498 | 991 | ||
| Repayments of long-term debt | (510) | (280) | ||
| Purchase of U.S. government obligations for the satisfaction and discharge of long-term debt | — | (647) | ||
| Common stock transactions: | ||||
| Issuances | 73 | 75 | ||
| Share repurchases | (2,846) | (2,347) | ||
| Dividends paid | (254) | (232) | ||
| Other | (496) | (152) | ||
| Net cash used in financing activities | (1,110) | (2,374) | ||
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | (21) | 6 | ||
| Net decrease in cash, cash equivalents, and restricted cash | (3,303) | (2,696) | ||
| Cash, cash equivalents, and restricted cash at beginning of period | 4,585 | 4,679 | ||
| Cash, cash equivalents, and restricted cash at end of period | 1,282 | 1,983 | ||
| Less: Restricted cash at end of period included in Prepaid expenses and other | (151) | (1) | ||
| Cash and cash equivalents at end of period | $ | 1,131 | $ | 1,982 |
Schedule 6
McKESSON CORPORATION
RECONCILIATION OF GAAP CASH FLOW TO FREE CASH FLOW (NON-GAAP)
(unaudited)
(in millions)
| Nine Months Ended December 31, | ||||||
|---|---|---|---|---|---|---|
| 2024 | 2023 | Change | ||||
| GAAP CASH FLOW CATEGORIES | ||||||
| Net cash provided by (used in) operating activities | $ | (1,663) | $ | 167 | — | % |
| Net cash used in investing activities | (509) | (495) | 3 | |||
| Net cash used in financing activities | (1,110) | (2,374) | (53) | |||
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | (21) | 6 | (450) | |||
| Net decrease in cash, cash equivalents, and restricted cash | $ | (3,303) | $ | (2,696) | 23 | % |
| FREE CASH FLOW (NON-GAAP) | ||||||
| Net cash provided by (used in) operating activities | $ | (1,663) | $ | 167 | — | % |
| Payments for property, plant, and equipment | (368) | (243) | 51 | |||
| Capitalized software expenditures | (213) | (175) | 22 | |||
| Free Cash Flow (Non-GAAP) | $ | (2,244) | $ | (251) | 794 | % |
Any percentage changes displayed above which are not meaningful are displayed as zero percent.
For more information relating to the Free Cash Flow (Non-GAAP) definition, refer to the section entitled “Supplemental Non-GAAP Financial Information” of this release.
1 of 2
McKESSON CORPORATION
FINANCIAL STATEMENT NOTES
(1)Transaction-related expenses and adjustments for the three and nine months ended December 31, 2024 includes a net loss of $23 million (pre-tax and after-tax) and $666 million (pre-tax and after-tax), respectively, to remeasure assets and liabilities held for sale to fair value less costs to sell related to an agreement to sell certain of our Canadian businesses. Net charges (pre-tax and after-tax) of $11 million included within International, and $12 million included within Corporate expenses, net, and $604 million included within International, and $62 million included within Corporate expenses, net, respectively, for the three and nine months ended December 31, 2024. These net charges are primarily to remeasure assets and liabilities held for sale to fair value less costs to sell, including the effect of accumulated other comprehensive income balances associated with the disposal group, and are included under "total operating expenses" in the reconciliation of McKesson's GAAP operating results to adjusted results (Non-GAAP) provided in Schedule 2 of the accompanying financial statement tables.
(2)Transaction-related expenses and adjustments for the three and nine months ended December 31, 2023 includes pre-tax gains of $2 million (pre-tax and after-tax) and $78 million ($58 million after-tax), respectively, related to fair value remeasurements of the contingent consideration liability recognized as part of our acquisition of Rx Savings Solutions, LLC. The gains, within Prescription Technology Solutions, resulted from remeasurement of the liability to fair value at the end of each reporting period based on the estimated amount and timing of projected operational and financial information and the probability of achievement of performance milestones. These pre-tax gains are included under "total operating expenses" in the reconciliation of McKesson's GAAP operating results to adjusted results (Non-GAAP) provided in Schedule 2 of the accompanying financial statement tables.
(3)Restructuring, impairment, and related charges, net for the three and nine months ended December 31, 2024 includes pre-tax charges of $32 million ($24 million after-tax) and $276 million ($204 million after-tax), respectively, primarily within Medical-Surgical Solutions, U.S. Pharmaceutical, and Corporate expenses, net. The three and nine months ended December 31, 2023 includes pre-tax charges of $4 million ($3 million after-tax) and $84 million ($63 million after-tax), respectively, primarily within Corporate expenses, net. These charges are included under "gross profit" and "total operating expenses" in the reconciliation of McKesson's GAAP operating results to adjusted results (Non-GAAP) provided in Schedule 2 of the accompanying financial statement tables.
(4)Claims and litigation charges, net for the nine months ended December 31, 2024 includes pre-tax charges of $114 million ($86 million after-tax) related to our estimated liability for opioid-related claims of a nationwide group of certain third-party payors. We recorded charges of $57 million ($43 million after-tax) within Corporate expenses, net and $57 million ($43 million after-tax) within U.S. Pharmaceutical. These charges are included under "total operating expenses" in the reconciliation of McKesson's GAAP operating results to adjusted results (Non-GAAP) provided in Schedule 2 of the accompanying financial statement tables.
(5)Other adjustments, net for the nine months ended December 31, 2024 includes a pre-tax credit of $203 million ($150 million after-tax), and for the three and nine months ended December 31, 2023 includes pre-tax charges of $515 million ($381 million after-tax) and $725 million ($536 million after-tax), respectively, within U.S. Pharmaceutical related to the bankruptcy petition filing of our customer, Rite Aid Corporation (including certain of its subsidiaries, "Rite Aid") filed in October 2023. The charge within the second quarter of fiscal 2024 represents the remaining uncollected trade accounts receivable balance as of September 30, 2023 due to us from Rite Aid. After Rite Aid successfully emerged from bankruptcy in August 2024, we reassessed our initial estimates made in conjunction with the previously reserved prepetition balances including cash received during the period, resulting in the credit recorded in the second quarter of fiscal 2025. Management believes the credit and charge are not reflective of allowances and estimated recoveries recorded in the normal course of operations and are related to Rite Aid's bankruptcy reorganization, and therefore are excluded from the determination of our adjusted results (Non-GAAP). These amounts are included under "total operating expenses" in the reconciliation of McKesson's GAAP operating results to adjusted results (Non-GAAP) provided in Schedule 2 of the accompanying financial statement tables.
(6)Other adjustments, net for the nine months ended December 31, 2024 includes a pre-tax charge of $43 million ($31 million after-tax) within U.S. Pharmaceutical related to a loss from one of the Company's investments in equity securities. This charge is included under "other income, net" in the reconciliation of McKesson's GAAP operating results to adjusted results (Non-GAAP) provided in Schedule 2 of the accompanying financial statement tables.
2 of 2
(7)During the nine months ended December 31, 2024, the Company recognized a pre-tax net gain of $100 million ($74 million after-tax) within Corporate expenses, net related to a recapitalization event of one of our investments in equity securities, which resulted in an increase to the carrying value of this investment. This gain was recorded in “Other income, net” in the Condensed Consolidated Statements of Operations (GAAP) provided in Schedule 1 of the accompanying financial statement tables.
1 of 3
McKESSON CORPORATION
SUPPLEMENTAL NON-GAAP FINANCIAL INFORMATION
In an effort to provide investors with additional information regarding the Company's financial results as determined by generally accepted accounting principles ("GAAP"), McKesson Corporation (the "Company" or "we") also presents the following Non-GAAP measures in this press release.
•Adjusted Gross Profit (Non-GAAP): We define Adjusted Gross Profit as GAAP gross profit, excluding transaction-related expenses and adjustments, last-in, first-out (“LIFO”) inventory-related adjustments, gains from antitrust legal settlements, and other adjustments.
•Adjusted Operating Expenses (Non-GAAP): We define Adjusted Operating Expenses as GAAP total operating expenses, excluding amortization of acquisition-related intangibles, transaction-related expenses and adjustments, restructuring, impairment, and related charges, claims and litigation charges, and other adjustments.
•Adjusted Other Income (Non-GAAP): We define Adjusted Other Income as GAAP other income (expense), net, excluding amortization of acquisition-related intangibles, transaction-related expenses and adjustments, and other adjustments.
•Adjusted Interest Expense (Non-GAAP): We define Adjusted Interest Expense as GAAP interest expense, excluding transaction-related expenses and adjustments related to net interest expense incurred from cross-currency swaps used to hedge the changes in the fair value of the Company's foreign currency-denominated notes resulting from changes in benchmark interest rates and foreign currency exchange rates. The foreign currency-denominated notes were previously designated as non-derivative net investment hedges of portions of the Company's net investments in its now-divested European businesses against the effect of exchange rate fluctuations on the translation of foreign currency balances to the U.S. dollar.
•Adjusted Income Tax Expense (Non-GAAP): We define Adjusted Income Tax Expense as GAAP income tax benefit (expense), excluding the income tax effects of amortization of acquisition-related intangibles, transaction-related expenses and adjustments, LIFO inventory-related adjustments, gains from antitrust legal settlements, restructuring, impairment, and related charges, claims and litigation charges, and other adjustments. Income tax effects are calculated in accordance with Accounting Standards Codification ("ASC") 740, “Income Taxes,” which is the same accounting principle used by the Company when presenting its GAAP financial results.
•Adjusted Earnings (Non-GAAP): We define Adjusted Earnings as GAAP income attributable to McKesson, excluding amortization of acquisition-related intangibles, transaction-related expenses and adjustments, LIFO inventory-related adjustments, gains from antitrust legal settlements, restructuring, impairment, and related charges, claims and litigation charges, other adjustments, as well as the related income tax effects for each of these items, as applicable.
•Adjusted Earnings per Diluted Share (Non-GAAP): We define Adjusted Earnings per Diluted Share as GAAP earnings per diluted common share attributable to McKesson, excluding per share impacts of amortization of acquisition-related intangibles, transaction-related expenses and adjustments, LIFO inventory-related adjustments, gains from antitrust legal settlements, restructuring, impairment, and related charges, claims and litigation charges, other adjustments, as well as the related income tax effects for each of these items, as applicable, divided by diluted weighted-average shares outstanding.
•Adjusted Segment Operating Profit (Non-GAAP) and Adjusted Segment Operating Profit Margin (Non-GAAP): We define Adjusted Segment Operating Profit as GAAP segment operating profit, excluding amortization of acquisition-related intangibles, transaction-related expenses and adjustments, LIFO inventory-related adjustments, gains from antitrust legal settlements, restructuring, impairment, and related charges, and other adjustments. We define Adjusted Segment Operating Profit Margin as Adjusted Segment Operating Profit (Non-GAAP) divided by GAAP segment revenues.
•Adjusted Corporate Expenses (Non-GAAP): We define Adjusted Corporate Expenses as GAAP corporate expenses, net, excluding transaction-related expenses and adjustments, restructuring, impairment, and related charges, claims and litigation charges, and other adjustments.
2 of 3
SUPPLEMENTAL NON-GAAP FINANCIAL INFORMATION (continued)
•Adjusted Operating Profit (Non-GAAP): We define Adjusted Operating Profit as GAAP income before interest expense and income taxes, excluding amortization of acquisition-related intangibles, transaction-related expenses and adjustments, LIFO inventory-related adjustments, gains from antitrust legal settlements, restructuring, impairment, and related charges, claims and litigation charges, and other adjustments.
The following provides further details regarding the adjustments made to our GAAP financial results to arrive at our Non-GAAP measures as defined above:
Amortization of acquisition-related intangibles - Amortization charges for intangible assets directly related to business combinations and the formation of joint ventures.
Transaction-related expenses and adjustments - Transaction, integration, and other expenses that are directly related to business combinations, the formation of joint ventures, divestitures, and other transaction-related costs including initial public offering costs. Examples include transaction closing costs, professional service fees, legal fees, severance charges, retention payments and employee relocation expenses, facility or other exit-related expenses, certain fair value adjustments including deferred revenues, contingent consideration and inventory, recoveries of acquisition-related expenses or post-closing expenses, net interest expense impact of hedging foreign currency-denominated notes, bridge loan fees and gains or losses on business combinations, and divestitures of businesses that do not qualify as discontinued operations.
LIFO inventory-related adjustments - LIFO inventory-related non-cash charges or credit adjustments.
Gains from antitrust legal settlements - Net cash proceeds representing the Company’s share of antitrust legal settlements.
Restructuring, impairment, and related charges - Restructuring charges that are incurred for programs in which we change our operations, the scope of a business undertaken by our business units, or the manner in which that business is conducted as well as long-lived asset impairments. Such charges may include employee severance, retention bonuses, facility closure or consolidation costs, lease or contract termination costs, asset impairments, accelerated depreciation and amortization, and other related expenses. The restructuring programs may be implemented due to the sale or discontinuation of a product line, reorganization or management structure changes, headcount rationalization, realignment of operations or products, integration of acquired businesses, and/or company-wide cost saving initiatives. The amount and/or frequency of these restructuring charges are not part of our underlying business, which include normal levels of reinvestment in the business. Any credit adjustments due to subsequent changes in estimates are also excluded from adjusted results.
Claims and litigation charges - Adjustments to certain of the Company’s reserves, including those related to estimated probable settlements for its controlled substance monitoring and reporting, and opioid-related claims, as well as any applicable income items or credit adjustments due to subsequent changes in estimates. This does not include our legal fees to defend claims, which are expensed as incurred. This also may include charges or credits for general non-operational claims not directly related to our ongoing business.
Other adjustments - The Company evaluates the nature and significance of transactions qualitatively and quantitatively on an individual basis and may include them in the determination of our adjusted results from time to time. While not all-inclusive, other adjustments may include: other asset impairments; gains or losses from debt extinguishment; and other similar substantive and/or infrequent items as deemed appropriate.
The Company evaluates the aforementioned Non-GAAP measures on a periodic basis and updates the definitions from time to time. The evaluation considers both the quantitative and qualitative aspects of the Company’s presentation of Non-GAAP adjusted results. A reconciliation of McKesson’s GAAP financial results to Non-GAAP financial results is provided in Schedules 2 and 3 of the financial statement tables included with this press release.
•Free Cash Flow (Non-GAAP): We define free cash flow as net cash provided by (used in) operating activities less payments for property, plant, and equipment and capitalized software expenditures, as disclosed in our condensed consolidated statements of cash flows. A reconciliation of McKesson’s GAAP financial results to Free Cash Flow (Non-GAAP) is provided in Schedule 6 of the financial statement tables included with this press release
3 of 3
SUPPLEMENTAL NON-GAAP FINANCIAL INFORMATION (continued)
The Company believes the presentation of Non-GAAP measures provides useful supplemental information to investors with regard to its operating performance, as well as assists with the comparison of its past financial performance to the Company’s future financial results. Moreover, the Company believes that the presentation of Non-GAAP measures assists investors’ ability to compare its financial results to those of other companies in the same industry. However, the Company's Non-GAAP measures used in the press tables may be defined and calculated differently by other companies in the same industry.
The Company internally uses both GAAP and Non-GAAP financial measures in connection with its own financial planning and reporting processes. Management utilizes Non-GAAP financial measures when allocating resources, deploying capital, as well as assessing business performance, and determining employee incentive compensation. The Company conducts its businesses internationally in local currencies, including Canadian dollars, Euro, and British pound sterling. As a result, the comparability of our results reported in U.S. dollars can be affected by changes in foreign currency exchange rates. We believe free cash flow is important to management and useful to investors as a supplemental measure as it indicates the cash flow available for working capital needs, re-investment opportunities, strategic acquisitions, share repurchases, dividend payments, or other strategic uses of cash. Nonetheless, Non-GAAP adjusted results and related Non-GAAP measures disclosed by the Company should not be considered a substitute for, nor superior to, financial results and measures as determined or calculated in accordance with GAAP.